Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 22 | 5,656 | 37% |
| 2020 | 23 | 6,167 | 40% |
| 2021 | 28 | 6,364 | 43% |
| 2022 | 24 | 5,731 | 46% |
| 2023 | 20 | 6,502 | 50% |
| 2024 | 21 | 7,289 | 54% |
| 2025 from claims | – | 8,966 8,229–9,486 | 54% |
| 2026 forecast | – | 9,515 8,372–10,980 | 54% |
| 2027 forecast | – | 10,045 8,587–11,970 | 55% |
| 2028 forecast | – | 10,602 8,847–12,982 | 56% |
| 2029 forecast | – | 11,188 9,138–14,031 | 57% |
| 2030 forecast | – | 11,805 9,457–15,127 | 57% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 77% of the cases CMS names in Washington; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 0% inpatient hospital, 22% hospital outpatient, 78% office. The share outside the hospital has moved +40 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~9,500 | ~1,900 | ~7,600 |
| 2027 · ~10,000 | ~1,900 | ~8,100 |
| 2028 · ~10,600 | ~2,000 | ~8,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 19% (22% in 2025), office about 81% (78% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 313 | 86,283+22%/yr | +22%/yr | 15.6 | 83% | 134,700 in 2030+7.7%/yr |
| Arizona | 83 | 15,125+16%/yr | +16%/yr | 12.6 | 85% | 26,900 in 2030+10%/yr |
| Nevada | 52 | 12,513+43%/yr | +43%/yr | 26.2 | 72% | 17,600 in 2030+5.9%/yr |
| Colorado | 27 | 6,374+23%/yr | +23%/yr | 7.8 | 82% | 11,000 in 2030+9.5%/yr |
| Utah | 18 | 5,940+21%/yr | +21%/yr | 16.2 | 77% | 5,190 in 2030−2.2%/yr |
| Oregon | 20 | 3,597+11%/yr | +11%/yr | 5.0 | 89% | 4,970 in 2030+5.5%/yr |
| Idaho | 11 | 2,190+7.1%/yr | +7.1%/yr | 6.8 | 51% | 4,080 in 2030+11%/yr |
| New Mexico | 9 | 2,075+17%/yr | +17%/yr | 5.6 | 92% | 2,610 in 2030+3.9%/yr |
| Montana | 9 | 1,642+11%/yr | +11%/yr | 6.7 | 62% | 1,670 in 2030+0.3%/yr |
| Hawaii | 3 | 546+7.6%/yr | +7.6%/yr | 2.4 | 74% | 1,080 in 2030+12%/yr |
| Wyoming | 0 | 397+25%/yr | +25%/yr | 3.2 | 90% | 650 in 2030+8.5%/yr |
| Alaska | 1 | 290−8.4%/yr | −8.4%/yr | 2.4 | 29% | 500 in 2030+9.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 208 | 44,361−4.5%/yr | −4.5%/yr | 55.20.5× | 41% | 45,700 in 2030+0.5%/yr |
| Bone graft & orthobiologics | 14 | 622−9.6%/yr | −9.6%/yr | 0.81.0× | 5% | 540 in 2030−2.4%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Organogenesis leads with 24% of company spending on these surgeons in 2025, +19 pts on 2024.
In 2025, 29 companies reported engagement with Washington’s surgeons worth $56K in consulting, speaking, meals and travel tied to these products, about $2,654 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.